- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01775904
A Study of Two Dosage Forms of LY2886721 in Healthy Participants
A Comparison Study of Capsule and Orally Disintegrating Tablet and to Determine the Effect of Food and Water on the Pharmacokinetics of LY2886721 in Healthy Subjects
The purpose of this study is to evaluate two different formulations of LY2886721. In addition, this study will determine how much of study drug (LY2886721) gets into the blood steam and how long the body takes to get rid of it after taking each formulation with or without a meal. Information about any side effects that may occur will also be collected. Each participant may be involved in the study for approximately 7 weeks.
This study requires 4 periods. In each period, participants will receive LY2886721 as a tablet or capsule, with or without food and water. There is a 7 day washout between each period.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2), inclusive, at screening
- At least 4 participants who are greater than 55 years of age
- Male participants: Agree to use a reliable method of birth control and not donate sperm during the study and for 3 months following the last dose of the investigational product
- Female participants: Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy, hysterectomy, or both) confirmed by medical history, or postmenopausal females, as determined by medical history and physical examination (spontaneous amenorrhea for 6 to 12 months and a follicle stimulating hormone [FSH] level greater than 40 milli-international units per milliliter [mIU/mL])
- Have venous access sufficient to allow for blood sampling as per the protocol
Exclusion Criteria:
- Are currently enrolled in, have completed, or discontinued within the last 30 days from a clinical trial involving an investigational product; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- Have participated, within the last 30 days, in a clinical trial involving an investigational product
- Have known allergies to LY2886721, related compounds, or any components of the formulation
- Have an abnormality in the 12-lead electrocardiogram (ECG)
- Have a significantly abnormal blood pressure as determined by the investigator
- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- Show evidence of hepatitis B or C and/or positive hepatitis B or C antibody
- Have a history of, or current, significant ophthalmologic disease
- Show evidence of significant active neuropsychiatric disease or history of suicide attempt
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY2886721 Capsule (water, fasting)
Reference formulation.
A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
|
Administered orally.
|
Experimental: LY2886721 ODT (no water, fasting)
A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
|
Administered orally.
|
Experimental: LY2886721 ODT (water, fed)
A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
|
Administered orally.
|
Experimental: LY2886721 ODT (water, fasting)
A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
|
Administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY2886721
Time Frame: Baseline through 96 hours post-dose
|
Baseline through 96 hours post-dose
|
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of LY2886721
Time Frame: Baseline through 96 hours post-dose
|
Baseline through 96 hours post-dose
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Time Tlast (AUC[0-tlast]) of LY2886721
Time Frame: Baseline through 96 hours post-dose
|
Baseline through 96 hours post-dose
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞] of LY2886721
Time Frame: Baseline through 96 hours post-dose
|
Baseline through 96 hours post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 14249
- I4O-MC-BACG (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on LY2886721 in a Capsule
-
Georgetown UniversityUnknownAlzheimer's DiseaseUnited States
-
Bristol-Myers SquibbRecruiting
-
University of East AngliaQuadram Institute BioscienceCompleted
-
Quan JiangUnknown
-
CytokineticsCompletedHealthy Subjects | Symptomatic Obstructive Hypertrophic CardiomyopathyUnited States
-
Evelo Biosciences, Inc.CompletedHealthy | DisintegrationUnited Kingdom
-
Micropharma LimitedCompletedHypercholesterolemiaCanada
-
Alexion PharmaceuticalsCelerionCompleted
-
Guang'anmen Hospital of China Academy of Chinese...UnknownKnee OsteoarthritisChina
-
Meng QiuRecruitingMucositis | Chemotherapeutic ToxicityChina